Drug intelligence / Profile preview

cnto 5825

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CNTO 5825 is a human monoclonal antibody that targets interleukin-13 (IL-13). It acts by inhibiting the binding of human IL-13 to its receptors, IL-13Rα1 and IL-13Rα2, thereby modulating immune responses associated with allergic diseases. Developed primarily for the treatment of allergic asthma, it was investigated in phase I clinical trials. The drug was originally developed by Centocor Ortho Biotech, which later became Janssen Biotech. Its mechanism of action is immunomodulation through specific inhibition of IL-13 signaling pathways[2][4][7][8].

Other names: Human monoclonal antibody (CNTO 5825)

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on cnto 5825.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cnto 5825.

Explore the full profile